Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Jaeger

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Blood Advances|February 20, 2020
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphomaRichard T Maziarz, Edmund K Waller, Ulrich Jaeger, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Hemasphere|March 9, 2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignanciesElise R A Pennings, Frederick W Thielen, Florence Broussais, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.
British Journal of Haematology|December 4, 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysisJennifer R Brown, Javid Moslehi, Michael S Ewer, et al.
Blood|November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitorsSonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Blood Advances|February 20, 2020
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphomaRichard T Maziarz, Edmund K Waller, Ulrich Jaeger, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Hemasphere|March 9, 2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignanciesElise R A Pennings, Frederick W Thielen, Florence Broussais, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.
British Journal of Haematology|December 4, 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysisJennifer R Brown, Javid Moslehi, Michael S Ewer, et al.
Blood|November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitorsSonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.
Pageof 11